Xbrane To File Ranibizumab Biosimilar In Europe And US Within 12 Months

Company Confirms Trials On Track For Approval Before Lucentis EU Patent Expiry

 
• By Akriti Seth

Sweden’s Xbrane is aiming to file for approval of its Xlucane (ranibizumab) biosimilar to Lucentis in Europe and the US, and license the rights for the product’s sale and marketing of in Latin America, Japan and China, in the next 12 months.

New Year Resolution Goal List 2020 - Business office desk with notebook written in handwriting about plan listing of new year goals and resolutions setting. Change and determination concept.
Xbrane lists multiple plans for the next 12 months • Source: Shutterstock

More from Biosimilars

More from Products